CCM
RCUS icon

Cutter Capital Management’s Arcus Biosciences RCUS Stock Holding History

Cutter Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-731,818
Closed -$5.74M – 15
2025
Q1 		$5.74M Buy
+731,818
New +$8.48M 2.5% 20
2024
Q1 		– Sell
-192,667
Closed -$3.68M – 35
2023
Q4 		$3.68M Buy
+192,667
New +$3.08M 1.76% 23

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Cutter Capital Management's RCUS Position: Q2 2025 in Review

Cutter Capital Management sold out of Arcus Biosciences (RCUS) in Q2 2025, closing a stake of 731,818 shares — an estimated $5.74M sold.

Cutter Capital Management first reported a position in RCUS in Q4 2023 and held it in 2 quarters. The position peaked at $5.74M in Q1 2025. 185 funds tracked by Wall St. Rank hold RCUS as of Q2 2025.

  • Cutter Capital Management reported no remaining Arcus Biosciences position as of Q2 2025 after selling out during the quarter.
  • Cutter Capital Management sold 731,818 Arcus Biosciences shares in Q2 2025, an estimated $5.74M.
  • Cutter Capital Management first reported a position in Arcus Biosciences in Q4 2023 and held it in 2 quarters.
  • Cutter Capital Management's Arcus Biosciences position peaked at $5.74M in Q1 2025.
  • 185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2025.

Based on Cutter Capital Management's 13F filing for Q2 2025.